Impact of an immune modulator fingolimod on acute ischemic stroke

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 51, 2014, Pages 18315-18320

  Fu, Ying ^a,b   Zhang, Ningnannan ^a   Ren, Li ^a   Yan, Yaping ^a   Sun, Na ^a   Li, Yu Jing ^a   Han, Wei ^a   Xue, Rong ^a   Liu, Qiang ^a,b   Hao, Junwei ^a   Yu, Chunshui ^a   Shi, Fu Dong ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Acute ischemic stroke; Fingolimod; Immune modulation

Indexed keywords

CD19 ANTIGEN; CD56 ANTIGEN; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ABNORMAL LABORATORY RESULT; ADULT; ANTERIOR CEREBRAL ARTERY; ARTICLE; ATRIOVENTRICULAR BLOCK; B LYMPHOCYTE; BLOOD VESSEL PERMEABILITY; BRADYCARDIA; BRAIN DAMAGE; BRAIN HERNIA; BRAIN ISCHEMIA; BRAIN MICROCIRCULATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG FEVER; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HERPES VIRUS INFECTION; HUMAN; IMMUNOMODULATION; LEUKOPENIA; LIVER FUNCTION TEST; LUNG INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MACULAR EDEMA; MALE; MICROVASCULATURE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN STUDY; PILOT STUDY; RECURRENT DISEASE; SIDE EFFECT; SINGLE BLIND PROCEDURE; STROKE PATIENT; TIME TO TREATMENT; TREATMENT DURATION; URINARY TRACT INFECTION; AGED; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; MIDDLE AGED; STROKE;

ADULT; AGED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; SINGLE-BLIND METHOD; SPHINGOSINE; STROKE;

EID: 84919884557     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416166111     Document Type: Article

References (39)

1. Hacke W, et al.; ECASS Investigators (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359(13):1317-1329.
2. Lees KR, et al.; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group (2010) Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375(9727):1695-1703.
3. Donnan GA, et al. (2011) How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 7(7):400-409.
4. Grossman AW, Broderick JP (2013) Advances and challenges in treatment and prevention of ischemic stroke. Ann Neurol 74(3):363-372.
5. Chamorro Á, et al. (2012) The immunology of acute stroke. Nat Rev Neurol 8(7):401-410.
6. Ahmad M, Graham SH (2010) Inflammation after stroke: Mechanisms and therapeutic approaches. Transl Stroke Res 1(2):74-84.
7. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364(7):656-665.
8. Iadecola C, Anrather J (2011) The immunology of stroke: From mechanisms to translation. Nat Med 17(7):796-808.
9. Mena H, Cadavid D, Rushing EJ (2004) Human cerebral infarct: A proposed histopathologic classification based on 137 cases. Acta Neuropathol 108(6):524-530.
10. Gan Y, et al. (2014) Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci USA 111(7):2704-2709.
11. Kleinschnitz C, et al. (2010) Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 115(18):3835-3842.
12. Shichita T, et al. (2009) Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15(8):946-950.
13. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH (2010) Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke 41(2):368-374.
14. Wei Y, et al. (2011) Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 69(1):119-129.
15. Massberg S, von Andrian UH (2006) Fingolimod and sphingosine-1-phosphate - Modifiers of lymphocyte migration. N Engl J Med 355(11):1088-1091.
16. Schwab SR, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741):1735-1739.
17. Cohen JA, Chun J (2011) Mechanisms of fingolimod' s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69(5):759-777.
18. Kappos L, et al.; FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401.
19. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS (2012) Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci USA 109(39):15930-15935.
20. Brunkhorst R, et al. (2013) FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS ONE 8(7):e70124.
21. Wacker BK, Park TS, Gidday JM (2009) Hypoxic preconditioning-induced cerebral ischemic tolerance: Role of microvascular sphingosine kinase 2. Stroke 40(10):3342-3348.
22. Czech B, et al. (2009) The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 389(2):251-256.
23. Pfeilschifter W, et al. (2011) Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med 9(3):2-7.
24. Pfeilschifter W, et al. (2011) Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia. Biochem Biophys Res Commun 413(2):212-217.
25. Kraft P, et al. (2013) FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 44(11):3202-3210.
26. Campos F, et al. (2013) Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke 44(2):505-511.
27. Gaudinski MR, et al. (2008) Establishing final infarct volume: Stroke lesion evolution past 30 days is insignificant. Stroke 39(10):2765-2768.
28. Liu HS, et al. (2013) Effects of microvascular permeability changes on contrastenhanced T1 and pharmacokinetic MR imagings after ischemia. Stroke 44(7):1872-1877.
29. Budde K, et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13(4):1073-1083.
30. Liesz A, et al. (2011) FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS ONE 6(6):e21312.
31. Hacke W, et al. (1996) 'Malignant' middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch Neurol 53(4):309-315.
32. Yang Y, Rosenberg GA (2011) Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42(11):3323-3328.
33. Schwamm LH, et al. (1998) Time course of lesion development in patients with acute stroke: Serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke 29(11):2268-2276.
34. Baird AE, et al. (1997) Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 41(5):581-589.
35. Liesz A, et al. (2011) Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134(Pt 3):704-720.
36. Moalem G, et al. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5(1):49-55.
37. Kohler E, et al. (2013) Intravenous minocycline in acute stroke: A randomized, controlled pilot study and meta-analysis. Stroke 44(9):2493-2499.
38. Endres M (2005) Statins and stroke. J Cereb Blood Flow Metab 25(9):1093-1110.
39. Fu Y, et al. (2014) Fingolimod for the treatment of intracerebral hemorrhage: A 2-arm proof-of-concept study. JAMA Neurol 71(9):1092-1101.